Appreciate the response.my view is that the recent CMS funding...

Appreciate the response.

my view is that the recent CMS funding agreement will significantly drive revenue in the next 6 months. Furthermore ,as impressive and complimentary as Imbios offering are , functional analysis ie airflow distribution is the better/more useful metric in diseased lung analysis. Hence , I can see no time wasted in existing clients of Imbio asking for XV scans. This sugar hit of revenue plus organic growth from
new commercial agreements, make this company far less risky .

this company has hit a new chapter beyond what the tea leaves are saying!